Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning: a Phase II Randomized Study From the Belgian Hematology Society (BHS)

NCT03852407 is registered in ClinicalTrials.gov with University of Liege as lead sponsor.

NCT NCT03852407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03852407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning: a Phase II Randomized Study From the Belgian Hematology Society (BHS)
Lead sponsor
University of Liege
Phase
Phase 2
Overall status
Recruiting
Start date
February 4, 2019
Completion date
November 1, 2038
Enrollment
114 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia in remission, acute myeloid leukemia in remission, chronic lymphoid leukemia, chronic myeloid leukemia in remission, hodgkin lymphoma, multiple myeloma, myelodysplastic syndromes, myeloproliferative disorder, myeloproliferative syndrome, non hodgkin lymphoma